Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: TECH

Bio-Techne Corporation

Healthcare | Biotechnology
$51.70 -2.48 (-4.58%) as of 2026-07-14 21:19 UTC
Market Cap$8.0B
EPS (TTM)$0.46

Bio-Techne Corporation (NASDAQ: TECH) is a $8.0B biotechnology company trading at $51.70 (−4.6% today) — 112.4× trailing earnings, yielding 0.61%. Figures from SEC EDGAR and market feeds; updated 2026-07-14 21:19 UTC.

52-Week Range
Low $51.13High $62.41

What Bio-Techne Corporation does

Bio-Techne Corporation develops, manufactures and sells life science reagents, instruments and services for research, diagnostics and bioprocessing markets globally. The company operates through two segments: Protein Sciences, which produces biological reagents and analytical tools used in life science research and drug discovery, and Diagnostics and Spatial Biology, which develops diagnostic products and tissue analysis instruments.

Summarized from Bio-Techne Corporation’s SEC filings · Read the filing ↗

Key facts
Quote
Price$51.70
Change (1D)-2.48 (-4.58%)
Market cap$8.0B
52-week range$51.13 – $62.41
Valuation
P/E (TTM)112.40×
EV/EBITDA37.00×
EPS (TTM)$0.46
Dividend yield0.61%
Price/book4.17×
Return on equity3.83%
Returns
52-week return+1.1%
Revenue, margins & earnings
FY2021 Net income: $140MFY2021 Taxes & interest: $97MFY2021 Operating expenses: $396MFY2021 Cost of revenue: $298M$931MFY2021FY2022 Net income: $272MFY2022 Taxes & interest: $25MFY2022 Operating expenses: $460MFY2022 Cost of revenue: $349M$1.11BFY2022FY2023 Net income: $285MFY2023 Taxes & interest: $14MFY2023 Operating expenses: $471MFY2023 Cost of revenue: $367M$1.14BFY2023FY2024 Net income: $168MFY2024 Taxes & interest: $39MFY2024 Operating expenses: $563MFY2024 Cost of revenue: $389M$1.16BFY2024FY2025 Net income: $73MFY2025 Taxes & interest: $29MFY2025 Operating expenses: $688MFY2025 Cost of revenue: $429M$1.22BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
Annual revenue; bands show net, operating, gross margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-06-04
  • 2026-06-04Crouse Steven C.President - Diag & Spatial BiM600—
  • 2026-06-04Crouse Steven C.President - Diag & Spatial BiF-216$10.8K
  • 2026-06-04Crouse Steven C.President - Diag & Spatial BiM-600—
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • VANGUARD GROUP INC17,307,339$1.02B-3.5%
  • VANGUARD CAPITAL MANAGEMENT LLC10,179,709$531.99MNEW
  • BlackRock, Inc.9,132,253$477.25M-24.7%
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Bio-Techne Corporation do?

Bio-Techne Corporation develops, manufactures and sells life science reagents, instruments and services for research, diagnostics and bioprocessing markets globally.

What is TECH's valuation?

TECH trades at $51.70, 112.40× trailing earnings, 37.00× EV/EBITDA, as of 2026-07-14. It carries a 0.61% dividend yield.

When did TECH last file with the SEC?

Bio-Techne Corporation's most recent SEC filing on record is a 8-K filed 2026-06-26. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 21:19 UTC. This page is also available as JSON at /api/data?ticker=TECH and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for TECH and 3,500+ tickers.

Create a free account — keep TECH
For your agent
GET /api/data?ticker=TECH

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt